Renew Biotechnologies Launches Epigenetic Diagnostic Tool for Male Fertility Assessment

Renew Biotechnologies, a nucleic-acid-based clinical development company, has advanced its epigenetic diagnostics portfolio with the launch of Path Fertility’s NOA Guide, a tool designed to support clinical decision-making for men with non-obstructive azoospermia (NOA). The diagnostic applies epigenetic analysis to assess testicular tissue and help clinicians determine the likelihood of sperm retrieval, informing treatment planning and patient counseling. The guide is intended to provide more objective insight than conventional assessments, which often rely on limited biomarkers or invasive procedures. The collaboration advances clinical applications that helps partners deliver emerging biological insights into clinically deployable diagnostics.

Male infertility remains an area with significant diagnostic gaps, particularly for complex conditions such as NOA. For fertility clinics and reproductive specialists, the NOA Guide reflects a broader shift toward precision diagnostics in reproductive medicine. By incorporating epigenetic data into clinical workflows, tools like this may help reduce unnecessary procedures, set clearer expectations and support more personalized fertility care.

Posted by MedCloudInsider Editors on 02/03/2026